Purchase of 'biosimilar' version of adalimumab, used to treat a range of conditions, may free up funds for more nurses The NHS is set to make a record-breaking saving after reaching deals with manufacturers on low-cost "biosimilar" versions of its most expensive drug, according to the health service's chief executive in England. The deal should save hospitals £300m, which equates to roughly three-quarters of the amount they currently spend, Simon Stevens will announce on Monday.
Purchase of 'biosimilar' version of adalimumab, used to treat a range of conditions, may free up funds for more nurses The NHS is set to make a record-breaking saving after reaching deals with manufacturers on low-cost "biosimilar" versions of its most expensive drug, according to the health service's chief executive in England. The deal should save hospitals £300m, which equates to roughly three-quarters of the amount they currently spend, Simon Stevens will announce on Monday.
Share this Article
Recommended